ASCCP Risk Based Consensus Guidelines for Management of Abnormal Cervical Cancer Screening Results

 

Ritu Nayar, MD
Professor and Vice Chair of Pathology
Director of Cytopathology
Northwestern University Feinberg School of Medicine Northwestern Memorial Hospital
Chicago, Illinois

Teresa M. Darragh, MD
Professor of Clinical Pathology
UCSF Mt. Zion Medical Center
San Francisco, California

 

The 2020 Risk-Based Management Consensus Guidelines have several important differences from the 2012 Guidelines, while retaining many of its principles, such as the principle of equal management for equal risk. Rather than consider test results in isolation, the new guidelines use current and past results to create individualized assessments of a patient’s risk of progressing to precancer or cancer. The body of research informing these guidelines demonstrated differences in risk of pre-cancer based on prior screening history, and specific screening results. Using this research, the guidelines Working Groups developed risk assessments to allow clinicians to better triage those likely to develop pre-cancer in the next five years. The risk assessments and resulting Clinical Action Thresholds recommend which patients require expedited treatment, further workup, or surveillance, as well as those who may return safely to routine screening. The goals of the ASCCP Risk-Based Management Consensus Guidelines are to increase accuracy and reduce complexity for providers and patients. Because the new Risk-Based Management Guidelines will be electronic, updates and new technologies will be incorporated at a much faster rate than in previous iterations of guidelines.

Target Audience

This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.

Learning Objectives

  • Understand the rationale behind using "risk" for management of abnormal cervical cancer screen results.
  • Understand the 2020 changes and updates to clinical management of abnormal cervical cancer screen results.
  • Understand implications of the 2020 ASCCP management guidelines for laboratories and pathologists.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 1.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 MOC II
  • 2.00 Participant
Course opens: 
08/25/2020
Course expires: 
08/31/2023
Cost:
$105.00
Presenters
 
Ritu Nayar, MD
Professor and Vice Chair of Pathology
Director of Cytopathology
Northwestern University Feinberg School of Medicine Northwestern Memorial Hospital
Chicago, Illinois
 
Teresa M. Darragh, MD
Professor of Clinical Pathology
UCSF Mt. Zion Medical Center
San Francisco, California
 
Disclosure
The presenters have no conflicts of interest or financial relationships to disclose.
 
Current ACCME guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect the speaker’s presentation(s). Therefore, it is the policy of the ASC to insure balance, independence, objectivity, and scientific rigor in all its educational programs.  All planning individuals participating in any ASC Educational Activity are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program.  Click here for a complete list.
 
ACCREDITATION AND DESIGNATION STATEMENTS

Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

American Board of Pathology Maintenance of Certification (CC)
This product can help fulfill the CME requirements and Self-Assessment Modules (SAMs) mandated by the American Board of Pathology Continuing Certification (CC) process.  Earn up to 2.0 SAM Credit Hours.

Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians.  The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the State of Florida and 1 in the State of California. The credit on each link is good for three years from the live presentation date.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 1.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 MOC II
  • 2.00 Participant

Price

Cost:
$105.00
Please login or register to take this course.